Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 52 pages report, published by Global Markets Direct

Keywords : Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Therapeutic Products under Development, Key Players in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Therapeutics, Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Pipeline Overview, Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Pipeline, Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Pipeline Assessment

Report ThumbnailJune-2017
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H1 2017

Summary

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H1 2017, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Addiction, Psychiatric Disorders, Alcohol Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, Dyskinesia, Major Depressive Disorder, Neurology and Pain.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • List of Figures
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • List of Tables
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Catalyst Biosciences Inc, H1 2017
  • Pipeline by H. Lundbeck A/S, H1 2017
  • Pipeline by NeuroDerm Ltd, H1 2017
  • Pipeline by Saniona AB, H1 2017
  • Pipeline by Sopharma AD, H1 2017
  • Pipeline by Suven Life Sciences Ltd, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Discontinued Products, H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Overview
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Companies Involved in Therapeutics Development
  • Catalyst Biosciences Inc
  • H. Lundbeck A/S
  • NeuroDerm Ltd
  • Saniona AB
  • Sopharma AD
  • Suven Life Sciences Ltd
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles
  • (nicotine + opipramol hydrochloride) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cytisine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NS-9283 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize nAChR Alpha-4 Beta-2 for Neurological and Psychiatric disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SUVN-911 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TC-8831 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TPI-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • varenicline tartrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Dormant Products
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Product Development Milestones
  • Featured News & Press Releases
  • May 25, 2017: Suven Life Sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a Neuronal Acetylcholine Nicotinic Receptor antagonist for Major Depressive Disorder
  • Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")
  • Dec 16, 2016: FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX (varenicline) Labeling
  • Sep 14, 2016: FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer’s Smoking Cessation Therapy, CHANTIX (varenicline)
  • May 23, 2016: CHAMPIX (Varenicline) European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP
  • Apr 22, 2016: CHANTIX/CHAMPIX (Varenicline) Results From The Largest Global Clinical Trial Of Smoking Cessation Medicines Published In The Lancet
  • Sep 04, 2015: Quit-smoking drug safer than thought
  • Mar 09, 2015: FDA updates label for stop smoking drug Chantix
  • Mar 09, 2015: Suven Life secures One (1) Product Patent each in Eurasia and Israel
  • Oct 16, 2014: Statement Regarding FDA Advisory Committees’ Vote on CHANTIX
  • Oct 06, 2014: US District Court Dismisses All Claims Related To Pfizer’s Chantix
  • Jan 21, 2014: CHANTIX/CHAMPIX (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly
  • Jun 03, 2013: NIH Researchers Find Varenicline As Promising Treatment For Alcohol Dependence
  • Feb 28, 2013: Pfizer Pays $273m For Settlement Of Lawsuits Related To Anti-smoking Drug Chantix
  • Jan 24, 2013: Pfizer's Chantix Demonstrates Efficacy In Smokers Who Previously Attempted To Quit Smoking With Chantix
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectNeuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H1 2017Product ThumbnailNeuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H1 2017, Industry ReportProduct #: 828998
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved